Coya Therapeutics prices upsized public offering of 4.18M shares at $5.50, raising ~$23M

Coya Therapeutics, Inc.

Offering of 3,636,364 shares (base) plus full exercise of 545,454 over-allotment, all at $5.50/share.
Gross proceeds of approximately $23.0 million; net proceeds for working capital and clinical development.
Directors and officers subject to lock-up restricting share sales until January 22, 2026.
Financial advisor to receive 100,000 warrants at $5.50 exercise price and $200,000 fee.
Lucid Capital Markets is sole book-runner; Allele Capital Partners acted as financial advisor.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.